Erik S.G Stroes, MD, PhD

Erik S.G Stroes, MD, PhD

Professor

Department of Vascular Medicine

Academic Medical Center

Amsterdam, The Netherlands

Related Videos

From the perspective of a lipid specialist, especially in light of the associated all-cause mortality reductions reported in ODYSSEY Outcomes, how should the clinician be thinking about PCSK9 inhibitors as a tool in their day-to-day practice? Video

From the perspective of a lipid specialist, especially in light of the associated all-cause mortality reductions reported in ODYSSEY Outcomes, how should the clinician be thinking about PCSK9 inhibitors as a tool in their day-to-day practice?

Can you describe the actual clinical phenotypes—actual patients referred to you by interventional or medical cardiologists—in which PCSK9 inhibition would represent a foundational approach to reduction of residual CV risk burden? Video

Can you describe the actual clinical phenotypes—actual patients referred to you by interventional or medical cardiologists—in which PCSK9 inhibition would represent a foundational approach to reduction of residual CV risk burden?

From a lipid medicine specialist’s perspective, what would your approach be to a post-ACS patient with two stents and triple-vessel disease whose LDL-C level is 70 mg/dL? Video

From a lipid medicine specialist’s perspective, what would your approach be to a post-ACS patient with two stents and triple-vessel disease whose LDL-C level is 70 mg/dL?

How vigorous should we be in trying to lower LDL-C in patients who have statin intolerance? What is the role of combined—so-called “backbone”—statin treatment plus PCSK9 inhibitor therapy? Video

How vigorous should we be in trying to lower LDL-C in patients who have statin intolerance? What is the role of combined—so-called “backbone”—statin treatment plus PCSK9 inhibitor therapy?

How should the lipid and atherosclerosis disease specialist interpret the ESC and AHA Guideline threshold of 70 mg/dL LDL-C level and determine whether even lower levels are even better to mitigate residual CV risk? Video

How should the lipid and atherosclerosis disease specialist interpret the ESC and AHA Guideline threshold of 70 mg/dL LDL-C level and determine whether even lower levels are even better to mitigate residual CV risk?